KR970032856A - 신경보호제 - Google Patents
신경보호제 Download PDFInfo
- Publication number
- KR970032856A KR970032856A KR1019960062011A KR19960062011A KR970032856A KR 970032856 A KR970032856 A KR 970032856A KR 1019960062011 A KR1019960062011 A KR 1019960062011A KR 19960062011 A KR19960062011 A KR 19960062011A KR 970032856 A KR970032856 A KR 970032856A
- Authority
- KR
- South Korea
- Prior art keywords
- rapamycin
- compound
- administering
- nmda
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
본 발명은 신경보호제로서 라파마이신, 페닐트리아졸린디온과의 라파마이신 1,3-디엘스 알더 부가물, 4-[[4-(디메틸아미노)페닐]아조]벤젠설폰산과의 라파마이신 42-에스테르, 메틸트리아졸린디온과의 라파마이신 1,3-디엘스 알더 부가물, 또는 라파마이신-O-벤질-27-옥심을 사용하는 방법을 제공한다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (14)
- 라파마이신, 페닐트리아졸린디온과의 라파마이시, 1,3-디엘스 알더(1,3-Diels Alder) 부가물, 4-[[4-(디메틸아미노)페닐]아조]벤젠설폰산과의 라파마이신 42-에스테르, 메틸트리아졸린디온과의 라파마이신 1,3-디엘스 알더 부가물, 및 라파마이신-O-벤질-27-옥심으로 이루어진 그룹중에서 선택된 화합물의 유효량을 이를 필요로 하는 포유동물에게 경구, 비경구, 혈관내, 비강내, 기관지내, 경피, 또는 직장투여하는 것을 포함하여, 상기 포유동물의 신경 세포 사멸을 억제하는 방법.
- 제1항에 있어서, 화합물이 라파마이신인 방법.
- 라파마이신, 페닐트리아졸린디온과의 라파마이신 1,3-디엘스 알더 부가물, 4-[[4-(디메틸아미노)페닐]아조]벤젠설폰산과의 라파마이신 42-에스테르, 메틸트리아졸린디온과의 라파마이신 1,3-디엘스 알더 부가물, 및 라파마이신-O-벤질-27-옥심으로 이루어진 그룹중에서 선택된 화합물의 유효량을 이를 필요로 하는 포유동물에게 경구, 비경구, 혈관내, 비강내, 기관지내, 경피, 또는 직장 투여하는 것을 포함하여, 상기 포유동물의 발작, 머리 손상 및 신경퇴화성 질환을 치료하는 방법.
- 제3항에 있어서, 화합물이 라파마이신인 방법.
- 제3항에 있어서, 신경퇴화성 질환이 알츠하이머 질환, 근위축성 외축 경화(ALS), 에피렙시, 헌팅톤 질환 (Huntington`s Diesease), 및 파키슨 질환으로 구성되는 그룹중에서 선택되는 방법.
- 제5항에 있어서, 화합물이 라파마이신인 방법.
- 라파마이신, 페닐트리아졸린디온과의 라파마이신 1,3-디엘스 알더 부가물, 4-[[4-(디메틸아미노)페닐]아조]벤젠설폰산과의 라파마이신 42-에스테르, 메틸트리아졸린디온과의 라파마이신 1,3-디엘스 알더 부가물, 및 라파마이신-O-벤질-27-옥심으로 이루어진 그룹중에서 선택된 화합물의 유효량을 이를 필요로 하는 포유동물에게 경구, 비경구, 혈관내, 비강내, 기관지내, 경피, 또는 직장 투여하는 것을 포함하는, 상기 화합물을 신경보호제로서 사용하는 방법.
- 제7항에 있어서, 화합물이 라파마이신인 방법.
- 제1항에 있어서, 상기 화합물을 N-메틸-D-아스파르테이트(NMDA) 또는 AMPA 길항제와 배합하여 투여하는 것을 추가로 포함하는 방법.
- 제1항에 있어서, 상기 화합물을 NMDA와 AMPA길항제 모두와 배합하여 투여하는 것을 추가로 포함하는 방법.
- 제3항에 있어서, 상기 화합물을 NMDA와 AMPA길항제와 배합하여 투여하는 것을 추가로 포함하는 방법.
- 제3항에 있어서, 상기 화합물을 NMDA 또는 AMPA길항제 모두와 배합하여 투여하는 것을 추가로 포함하는 방법.
- 제7항에 있어서, 상기 화합물을 NMDA 또는 AMPA길항제와 배합하여 투여하는 것을 추가로 포함하는 방법.
- 제7항에 있어서, 상기 화합물을 NMDA와 AMPA길항제 모두와 배합하여 투여하는 것을 추가로 포함하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US833795P | 1995-12-07 | 1995-12-07 | |
US60/008,337 | 1995-12-07 | ||
ITRM95A000824 | 1995-12-15 | ||
FR95-15335 | 1995-12-22 | ||
JP7-337558 | 1995-12-25 | ||
JP7-337557 | 1995-12-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR970032856A true KR970032856A (ko) | 1997-07-22 |
Family
ID=21731060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019960062011A KR970032856A (ko) | 1995-12-07 | 1996-12-05 | 신경보호제 |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP0778023B1 (ko) |
JP (1) | JPH09183727A (ko) |
KR (1) | KR970032856A (ko) |
CN (1) | CN1112925C (ko) |
AR (1) | AR008747A1 (ko) |
AT (1) | ATE234095T1 (ko) |
AU (1) | AU700653B2 (ko) |
BR (1) | BR9605895A (ko) |
CA (1) | CA2192298A1 (ko) |
CZ (2) | CZ6498A3 (ko) |
DE (1) | DE69626610T2 (ko) |
DK (1) | DK0778023T3 (ko) |
ES (1) | ES2188730T3 (ko) |
HU (1) | HUP9603370A3 (ko) |
IL (1) | IL119778A (ko) |
MX (1) | MX9606131A (ko) |
NO (1) | NO309966B1 (ko) |
NZ (1) | NZ299888A (ko) |
PT (1) | PT778023E (ko) |
SI (1) | SI0778023T1 (ko) |
SK (1) | SK154796A3 (ko) |
TW (1) | TW427904B (ko) |
ZA (1) | ZA9610245B (ko) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1002535A1 (en) * | 1998-10-28 | 2000-05-24 | Hrissanthi Ikonomidou | New use of glutamate antagonists for the treatment of cancer |
US7253169B2 (en) | 1999-11-12 | 2007-08-07 | Gliamed, Inc. | Aza compounds, pharmaceutical compositions and methods of use |
US6417189B1 (en) * | 1999-11-12 | 2002-07-09 | Gpi Nil Holdings, Inc. | AZA compounds, pharmaceutical compositions and methods of use |
FR2806626B1 (fr) * | 2000-03-22 | 2003-11-28 | Centre Nat Rech Scient | Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues |
WO2001079177A1 (en) * | 2000-04-17 | 2001-10-25 | Gpi Nil Holdings, Inc. | Cyclic diaza compounds for treating neurodegenerative disorders |
GB0117645D0 (en) | 2001-07-19 | 2001-09-12 | Isis Innovation | Therapeutic stratergies for prevention and treatment of alzheimers disease |
UA78529C2 (en) | 2001-10-10 | 2007-04-10 | Wyeth Corp | Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain |
US20030176455A1 (en) * | 2002-03-13 | 2003-09-18 | Wyeth | Method of inhibiting cell death |
WO2004091633A1 (en) * | 2003-04-09 | 2004-10-28 | Wyeth | Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.o]non-1 (7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof |
DE602004029146D1 (de) | 2003-04-09 | 2010-10-28 | Wyeth Llc | Derivate von 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkylphosphonsäure und deren verwendung als n-methyl-d-aspartat- (nmda-) rezeptorantagonisten |
WO2004089369A2 (en) * | 2003-04-11 | 2004-10-21 | Cambridge University Technical Services Limited | Methods and means for treating protein conformational disorders |
US7485706B2 (en) * | 2003-07-30 | 2009-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Neurodegenerative protein aggregation inhibition methods and compounds |
GT200400213A (es) | 2003-10-22 | 2007-09-05 | Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo | |
BRPI0519495A2 (pt) | 2004-12-20 | 2009-02-03 | Wyeth Corp | composto ou um sal farmaceuticamente aceitÁvel do mesmo, uso de um composto, e, mÉtodo para preparar um composto |
KR20070090931A (ko) | 2004-12-20 | 2007-09-06 | 와이어쓰 | 라파마이신 유도체 및 신경계장애의 치료에서의 그의 용도 |
JP4857071B2 (ja) * | 2006-10-12 | 2012-01-18 | 潤平 笹部 | 筋萎縮性側策硬化症(als)の検出方法 |
EP2065038A1 (en) | 2007-11-30 | 2009-06-03 | Pharnext | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
EP2135607A1 (en) | 2008-06-18 | 2009-12-23 | Pharnext | Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders |
BRPI1010655A2 (pt) * | 2009-04-10 | 2019-09-03 | Qi Haiyan | novos agentes antienvelhecimento e métodos para identificá-los |
EP2263665A1 (en) | 2009-06-02 | 2010-12-22 | Pharnext | New compositions for treating CMT and related disorders |
US9393241B2 (en) | 2009-06-02 | 2016-07-19 | Pharnext | Compositions for treating CMT and related disorders |
CA2768710A1 (en) * | 2009-07-24 | 2011-01-27 | Institut National De La Recherche Scientifique | Combinations of curcuminoids and mtor inhibitors for the treatment of tauopathies |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
US9121859B2 (en) | 2012-12-04 | 2015-09-01 | Siemens Healthcare Diagnostics Inc. | Compounds and methods for determination of FKBP-binding immunosuppressant drugs |
CN113209101A (zh) | 2013-06-05 | 2021-08-06 | 法奈克斯公司 | 用于组合的活性药物成分的稳定口服溶液 |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
US10383870B2 (en) | 2016-06-10 | 2019-08-20 | Pharnext | Early treatment of CMT disease |
JP2021502971A (ja) * | 2017-11-15 | 2021-02-04 | ヴァンダービルト ユニヴァーシティ | リソソーム機能の改善および神経変性疾患の治療のための方法および組成物 |
CN114366738A (zh) * | 2021-12-20 | 2022-04-19 | 中国人民解放军军事科学院军事医学研究院 | 雷帕霉素在促进神经干细胞扩增中的用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0532862A1 (en) * | 1991-07-25 | 1993-03-24 | University Of Louisville Research Foundation, Inc. | Use of rapamycin for the preparation of a medicament for the treatment of ocular inflammation |
JPH05170668A (ja) * | 1991-06-05 | 1993-07-09 | Schering Ag | パーキンソン症候群を治療するための薬剤学的製剤 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
JPH04230389A (ja) * | 1990-07-16 | 1992-08-19 | American Home Prod Corp | ラパマイシン誘導体 |
US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
IL101353A0 (en) * | 1991-04-03 | 1992-11-15 | American Home Prod | Pharmaceutical compositions for treating diabetes |
US5260299A (en) * | 1992-03-05 | 1993-11-09 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents |
IL111003A0 (en) * | 1993-09-30 | 1994-11-28 | American Home Prod | Multi-component oral rapamycin formulation |
-
1996
- 1996-11-28 TW TW085114700A patent/TW427904B/zh not_active IP Right Cessation
- 1996-12-04 AT AT96308786T patent/ATE234095T1/de not_active IP Right Cessation
- 1996-12-04 ES ES96308786T patent/ES2188730T3/es not_active Expired - Lifetime
- 1996-12-04 SI SI9630586T patent/SI0778023T1/xx unknown
- 1996-12-04 CZ CZ9864A patent/CZ6498A3/cs unknown
- 1996-12-04 EP EP96308786A patent/EP0778023B1/en not_active Expired - Lifetime
- 1996-12-04 DE DE69626610T patent/DE69626610T2/de not_active Expired - Fee Related
- 1996-12-04 CZ CZ963544A patent/CZ354496A3/cs unknown
- 1996-12-04 DK DK96308786T patent/DK0778023T3/da active
- 1996-12-04 PT PT96308786T patent/PT778023E/pt unknown
- 1996-12-04 SK SK1547-96A patent/SK154796A3/sk unknown
- 1996-12-05 MX MX9606131A patent/MX9606131A/es unknown
- 1996-12-05 NZ NZ299888A patent/NZ299888A/en unknown
- 1996-12-05 ZA ZA9610245A patent/ZA9610245B/xx unknown
- 1996-12-05 AU AU74178/96A patent/AU700653B2/en not_active Ceased
- 1996-12-05 KR KR1019960062011A patent/KR970032856A/ko not_active Application Discontinuation
- 1996-12-06 BR BR9605895A patent/BR9605895A/pt not_active Application Discontinuation
- 1996-12-06 AR ARP960105543A patent/AR008747A1/es not_active Application Discontinuation
- 1996-12-06 CN CN96123098A patent/CN1112925C/zh not_active Expired - Fee Related
- 1996-12-06 JP JP8326582A patent/JPH09183727A/ja active Pending
- 1996-12-06 IL IL11977896A patent/IL119778A/xx not_active IP Right Cessation
- 1996-12-06 NO NO965238A patent/NO309966B1/no not_active IP Right Cessation
- 1996-12-06 HU HU9603370A patent/HUP9603370A3/hu unknown
- 1996-12-06 CA CA002192298A patent/CA2192298A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05170668A (ja) * | 1991-06-05 | 1993-07-09 | Schering Ag | パーキンソン症候群を治療するための薬剤学的製剤 |
EP0532862A1 (en) * | 1991-07-25 | 1993-03-24 | University Of Louisville Research Foundation, Inc. | Use of rapamycin for the preparation of a medicament for the treatment of ocular inflammation |
JPH05194212A (ja) * | 1991-07-25 | 1993-08-03 | Univ Louisville Res Found Inc | 眼炎症処置方法 |
Also Published As
Publication number | Publication date |
---|---|
HU9603370D0 (en) | 1997-01-28 |
CN1112925C (zh) | 2003-07-02 |
SK154796A3 (en) | 1997-09-10 |
DE69626610D1 (de) | 2003-04-17 |
NZ299888A (en) | 2001-02-23 |
ES2188730T3 (es) | 2003-07-01 |
CZ354496A3 (cs) | 1998-03-18 |
AR008747A1 (es) | 2000-02-23 |
EP0778023A1 (en) | 1997-06-11 |
BR9605895A (pt) | 1998-08-18 |
MX9606131A (es) | 1997-08-30 |
DK0778023T3 (da) | 2003-06-30 |
PT778023E (pt) | 2003-06-30 |
ATE234095T1 (de) | 2003-03-15 |
CN1159915A (zh) | 1997-09-24 |
IL119778A0 (en) | 1997-03-18 |
CZ6498A3 (cs) | 1998-06-17 |
AU700653B2 (en) | 1999-01-14 |
ZA9610245B (en) | 1998-06-05 |
TW427904B (en) | 2001-04-01 |
SI0778023T1 (en) | 2003-08-31 |
CA2192298A1 (en) | 1997-06-08 |
HUP9603370A2 (en) | 1997-05-28 |
IL119778A (en) | 1999-07-14 |
DE69626610T2 (de) | 2003-10-02 |
JPH09183727A (ja) | 1997-07-15 |
AU7417896A (en) | 1997-06-12 |
EP0778023B1 (en) | 2003-03-12 |
HUP9603370A3 (en) | 1998-12-28 |
NO965238L (no) | 1997-06-09 |
NO309966B1 (no) | 2001-04-30 |
NO965238D0 (no) | 1996-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR970032856A (ko) | 신경보호제 | |
BR9814923A (pt) | Método para tratamento de doença de alzheimer | |
KR940005633A (ko) | 약제학적으로 유용한 항경련제 설파메이트의 이미데이트 유도체 | |
BR0005276A (pt) | Compostos para o tratamento de disfução sexual feminina | |
BRPI0407922A (pt) | derivados de isoquinolina e métodos de uso destes | |
MA25809A1 (fr) | Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase | |
BR0207316A (pt) | Derivados de epotilona para o tratamento de tumores refratários | |
ATE205493T1 (de) | N-aminoalkyldibenzofuran-carboxamide als dopaminrezeptor-subtyp spezifische liganden | |
BR0314390A (pt) | Moduladores aromáticos dos receptores hepáticos x | |
BR0113389A (pt) | Compostos que inibem a atividade do fator xa | |
KR950016740A (ko) | 조직의 불완전한 회복을 저해하는 방법 | |
BR0016217A (pt) | Composto, processo para prepará-lo, composição farmacêutica, e, uso do composto | |
ATE201676T1 (de) | N-azacycloalkylalkyldibenzothiophencarboxamide: spezifische liganden für dopaminrezeptorsubtypen | |
PT838223E (pt) | Inibidor do edema cerebral | |
Haug et al. | The combination of donepezil and procyclidine protects against soman-induced seizures in rats | |
NZ507303A (en) | Quinolin-4-yl derivatives II and their use in treating neurodegenerative disease | |
Fuller et al. | Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist | |
LV11320A (lv) | 1-arilcikloalkilsulfida sulfoksida vai sulfona atvasinajumu pielietosana depresijas satraukuma Parkinsona slimibas arstesanai | |
CO4410322A1 (es) | Nuevos compuestos de carboxamida, sus sales farmaceuticamente aceptables y composiciones farmaceuticas que los contienen | |
NO980531D0 (no) | Medikament for hemming av avhengighets og toleranse utviklet som fölge av et narkotisk smertestillende middel | |
BR0112338A (pt) | Composto, composição farmacêutica, e, uso de um composto | |
BR0015404A (pt) | Compostos relacionados com ácido 15-hidroxieicosatetraenóico e métodos de uso | |
KR950016720A (ko) | 아밀로이드 단백질의 효과를 저해하는 방법 | |
BR9910185A (pt) | Uso de um composto, e, processo para o tratamento de um paciente que sofre de, ou em risco de, uma doença micobacteriana | |
Pugsley | On the lex Aquilia and culpa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |